About Zhejiang Beta Pharma
Beta Pharma is a Chinese biotech company focused on the development of therapies for cancer and inflammatory diseases. In 2011, the company received Chinese FDA approval for its "Class One" new drug Icotinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) in China. Icotinib is the first commercialized project in China's "Significant Innovative Drug Development" program. Beta Pharma is headquartered in Hangzhou, with its R&D center located in Beijing.